KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medtronic (MDT) Interest Expenses (2016 - 2026)

Medtronic's Interest Expenses history spans 13 years, with the latest figure at $181.0 million for Q1 2026.

  • On a quarterly basis, Interest Expenses rose 1.12% to $181.0 million in Q1 2026 year-over-year; TTM through Jan 2026 was $712.0 million, a 5.94% decrease, with the full-year FY2025 number at $729.0 million, up 1.39% from a year prior.
  • Interest Expenses hit $181.0 million in Q1 2026 for Medtronic, roughly flat from $181.0 million in the prior quarter.
  • Over the last five years, Interest Expenses for MDT hit a ceiling of $209.0 million in Q4 2024 and a floor of $118.0 million in Q4 2022.
  • Historically, Interest Expenses has averaged $170.6 million across 5 years, with a median of $176.0 million in 2025.
  • Biggest five-year swings in Interest Expenses: soared 52.54% in 2023 and later decreased 13.86% in 2025.
  • Tracing MDT's Interest Expenses over 5 years: stood at $118.0 million in 2022, then surged by 52.54% to $180.0 million in 2023, then rose by 16.11% to $209.0 million in 2024, then fell by 13.4% to $181.0 million in 2025, then changed by 0.0% to $181.0 million in 2026.
  • Business Quant data shows Interest Expenses for MDT at $181.0 million in Q1 2026, $181.0 million in Q4 2025, and $176.0 million in Q3 2025.